Rallybio Corporation

AMAG Pharmaceuticals

Disc Medicine

13F fund flow: neutral, ? institutional managers

1 PubMed publications found for Rallybio Corporation

Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations.

SW convergence: 50/100 (Neutral), 0 bullish / 0 bearish signals

<article class="bts-verified-summary" data-ticker="RALLB">
<p>Rallybio Corporation (RALLB) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.</p>
<p>No Form 4 insider filings for RALLB were recorded at the SEC in the past 30 days<sup><a href="#fn-1">[1]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">SEC EDGAR (2026-06-17) <a href="https://efts.sec.gov/LATEST/search-index?q=%22RALLB%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-05-18&amp;enddt=2026-06-17" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

SEC EDGAR

Rallybio Corporation (RALLB) — BioTechSigns Verified Summary

Rallybio Corporation (RALLB) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.

No Form 4 insider filings for RALLB were recorded at the SEC in the past 30 days[1].

Sources:
[1] SEC EDGAR. Source last updated 2026-06-17, retrieved 2026-06-17.
    https://efts.sec.gov/LATEST/search-index?q=%22RALLB%22&forms=4&dateRange=custom&startdt=2026-05-18&enddt=2026-06-17